Moonlight Therapeutics Initiates Phase I Clinical Trial (SURVEYOR) of MOON101 for Peanut Allergy
Moonlight Therapeutics, Inc., a clinical stage biotechnology company developing a proprietary intradermal immunotherapy platform for food allergies, today announced the initiation of SURVEYOR, a Phase I clinical trial, evaluating MOON101 for the treatment of peanut allergy, marking the program’s transition into clinical-stage development.
